Skip to main content
Premium Trial:

Request an Annual Quote

Ambry Genetics to Use RainDance Microdroplet PCR Tech in Diagnostics, Genomic Research Services


Ambry Genetics will use RainDance Technologies' microdroplet- based PCR technology as part of its diagnostics and genomics services, the companies said this week.

Under the partnership, Ambry will incorporate RainDance's RDT 1000 platform into sequence-enrichment and targeted resequencing applications.

Ambry's customers in the diagnostics, genomics, and research arenas can now use the RDT 1000 as part of their sequence enrichment or resequencing efforts to reduce study time or improve study quality by running more samples in the same time with the same budget, the companies said.

In addition to currently offering RainDance's sequence-enrichment platform, Ambry may use the RainDance platform for methyl-seq and ultra-deep resequencing applications in the second half of 2010.

"PCR is the gold standard for sequence enrichment and allows for high-resolution analysis of rare genetic variations, a focus area of Ambry Genetics' customers," RainDance Chief Commercial Officer Chris McNary said in a statement.

Ambry, based in Aliso Viejo, Calif., is a CAP-accredited and CLIA-certified commercial clinical laboratory.

Ardy Arianpour, Ambry's director of business development, said in a statement that the RainDance platform "adds a sequence-enrichment offering while providing an option to customers that are in need of high-throughput targeted sequencing with a high level of coverage, completeness, and speed."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.